Diversified Consumer Services
Company Overview of University of Southern California
University of Southern California is an educational institution that offers accounting, computer science, civil engineering, advertising, and management programs. The schools of the university include The College of Letters, Arts and Sciences, which offers undergraduate, graduate, and doctoral degrees in over 30 academic departments such as sciences and social sciences, civic and cultural studies, and international and language studies; The Graduate School focuses on academic and professional affairs of the university; and Professional Schools including the Schools of Pharmacy and Medicine. The institution was founded in 1880 and is based in Los Angeles, California.
University Park Campus
Los Angeles, CA 90089
Founded in 1880
Key Executives for University of Southern California
Chief Financial Officer and Senior Vice President, Finance
Vice President of Student Affairs
Senior Vice President of Advancement
Compensation as of Fiscal Year 2015.
University of Southern California Key Developments
University of Southern California Presents at AusBiotech National Conference 2015, Oct-08-2015 09:00 AM
Oct 5 15
University of Southern California Presents at AusBiotech National Conference 2015, Oct-08-2015 09:00 AM. Venue: Victoria, Australia. Speakers: Dushyant Pathak, Associate Vice Chancellor, Office of Research Technology Management & Corporate Relations.
The University of Southern California Wins $4.69 Million Federal Contract
Sep 2 15
The University of Southern California won a $4,689,063 federal contract from the Defense Advanced Research Projects Agency, Arlington, Virginia, for R&D on low resource languages for emergent incidents (LORELEI).
Caladrius Biosciences, Inc. Announces Research Collaboration with the University of Southern California and California Institute of Technology
Jun 18 15
Caladrius Biosciences, Inc. announced that it has entered into a material transfer agreement with the University of Southern California and the California Institute of Technology, concerning next-generation strategies for its core cancer technology. This research collaboration will build on Caladrius' highly successful manufacturing protocol for its lead cancer program, CLBS20 (aka NBS20), by exploring techniques to further enhance the isolation of cancer initiating cells with the goal of increasing the number of cancer patients that might benefit from treatment. CLBS20 is the subject of a Phase 3 clinical trial investigating its efficacy in the treatment of late-stage melanoma, the Intus Study. The trial has been granted a Special Protocol Assessment by the US Food and Drug Administration (FDA) and the CLBS20 development program has been granted Orphan Drug and Fast Track designations by FDA. Randomization of the first patient in the Intus trial occurred in April 2015. Advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are 20,000 estimated new cases, and an estimated 10,000 deaths, from metastatic melanoma each year in the United States. The US melanoma market is approximately $1 billion per year, which is predominantly spent to treat metastatic melanoma. The platform on which CLBS20 is based is potentially applicable across multiple solid tumor types, including lung, colon and ovarian cancer, hepatocellular carcinoma and glioblastoma multiforme. CLBS20 uses the patient's own immune cells and tumor-initiating cells to create an immunotherapy therapeutic vaccine. It is unique in targeting these cancer- or tumor-initiating cells; other therapies, which target different tumor cells, may treat existing cancer but may not be as likely to prevent tumor recurrence.
Similar Private Companies By Industry
Recent Private Companies Transactions